Compare Illumina, Inc. (ILMN) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Nutrien Ltd — how do they compare? Illumina, Inc. trades at $190.45 (market cap $27.94B), while Nutrien Ltd trades at $66.71 (market cap $31.67B). The key difference: Illumina, Inc. and Nutrien Ltd are close in size by market cap, and Nutrien Ltd pays a 3.3% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | NTR | |
|---|---|---|
Market Cap | $27.94B | $31.67B |
Sector | Health | Basic Materials |
52-Week High | $194.33 | $83.94 |
52-Week Low | $91.00 | $53.64 |
Enterprise Value | $29.33B | $44.84B |
Dividend Yield | — | 3.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Nutrien (NTR) trades at $66.40, down 1.31% on the day, with a bullish technical outlook supported by moving averages. The company shows improving fundamentals with Q1 2026 EPS beating expectations at $0.51 versus $0.48, and revenue trending upward to $26.89B in 2025. Valuation ratios appear attractive with a P/E of 13.7 and P/S of 1.17. Analyst sentiment is positive with a consensus price target of $77.67, representing 17% upside, and 61% of analysts rate it a Buy.
The outlook for Nutrien is favorable due to strong fertilizer demand and cost management, though risks include volatile input costs and competitive pressures. With solid cash flow from operations and a dividend payout, the stock offers value and income potential, but investors should monitor global agricultural trends and energy market impacts on margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
